Forex News
NurExone Biologic Inc.-RedChip agreement fee: 65000
NurExone Biologic Inc. has an investor relations agreement with RedChip Companies, Inc., one account says; the fee is 65000.
Commercial activity
One source lists NurExone Biologic Inc.’s investor relations agreement with RedChip Companies, Inc. and puts the fee at 65000.
Reported details describe the company’s advertisement campaign as a two-week national television campaign.
Made Scientific is named in one account as the counterparty to NurExone Biologic Inc.’s memorandum of understanding.
A source lists NurExone Biologic Inc.’s participation in four major life sciences events.
Therapeutic candidate
One account identifies ExoPTEN as NurExone Biologic Inc.’s lead therapeutic candidate.
A source reports preclinical data for ExoPTEN in acute spinal cord and optic nerve damage.
Leadership
One account identifies Dr. Lior Shaltiel as CEO of NurExone Biologic Inc..
Dr. Tali Kizhner is identified as R&D Director of NurExone Biologic Inc. in a single account.